As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Imunon, Inc. The largest reported stake is Armistice Capital, LLC's, at 9.99%. 5 filings are on record since August 12, 2025 (Schedule 13G/A, August 14, 2026).
Sell to companies like Imunon, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Armistice Capital, LLC · Sole voting: 0 · Shared voting: 450,315 · Sole dispositive: 0 · Shared dispositive: 450,315 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Armistice Capital, LLC · Percent: 9.99% · SCHEDULE 13G/A
- · Holder: Armistice Capital, LLC · Percent: 9.99% · SCHEDULE 13G
- · Reporting person: Ayrton Capital LLC · Sole voting: 2,000 · Shared voting: 0 · Sole dispositive: 2,000 · Shared dispositive: 0 · SCHEDULE 13G/A, 2025-08-13
- · Holder: Mitchell P. Kopin · Percent: 4.99% · SCHEDULE 13G/A
Imunon, Inc. has 5 Schedule 13D or 13G filings on record since 2025-08-12. 1 holder's latest filing reports 5% or more of common stock, par value $0.01 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.99% | 450,315 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| 4.99% | 1,067,196 | SCHEDULE 13G/A, 2025-08-12 | 2025-06-30 | |
| Ayrton Capital LLC | 0% | 2,000 | SCHEDULE 13G/A, 2025-08-13 | 2025-06-30 |
Holding shares or following this stake? See who's behind Imunon, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Imunon, Inc. and the records around it.
Imunon, Inc. elsewhere on the record
- Leadership changes Aug 2026
- Form D filing May 2025
- Who owns it
Companies that share a holder
- Ayrton Capital LLC also filed stake reports on 31 other companies: Bluejay Diagnostics, Inc. (Aug 2026), BTC Digital Ltd. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026)
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Imunon, Inc.
Get an email when Imunon, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Imunon, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Imunon, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Imunon, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 0 | 450,315 | 0 | 450,315 | SCHEDULE 13G/A, 2026-08-14 |
| Steven Boyd | 0 | 450,315 | 0 | 450,315 | SCHEDULE 13G/A, 2026-08-14 |
| Ayrton Capital LLC | 2,000 | 0 | 2,000 | 0 | SCHEDULE 13G/A, 2025-08-13 |
| Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B | 2,000 | 0 | 2,000 | 0 | SCHEDULE 13G/A, 2025-08-13 |
| Waqas Khatri | 2,000 | 0 | 2,000 | 0 | SCHEDULE 13G/A, 2025-08-13 |
The latest filing identifies Imunon, Inc. by CUSIP 15117N701 and gives its principal executive office as 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648 (SCHEDULE 13G/A, 2026-08-14).
What the percentages are based on
The percentages below are based on 17,541,732 shares of Common Stock of the Issuer that were outstanding as of May 16, 2025 held by the Reporting Persons. The amount of shares outstanding was based upon a statement in the Issuer's Form S-1/A filed on May 19, 2025.Ayrton Capital LLC, SCHEDULE 13G/A, 2025-08-13
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | Mitchell P. Kopin | 4.99% | SCHEDULE 13G/A |
| 2025-08-13 | Ayrton Capital LLC | 0% | SCHEDULE 13G/A |
| 2026-02-17 | Armistice Capital, LLC | 9.99% | SCHEDULE 13G |
| 2026-05-15 | Armistice Capital, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-08-14 | Armistice Capital, LLC | 9.99% | SCHEDULE 13G/A |
Questions about who owns Imunon, Inc.
Who owns Imunon, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Imunon, Inc.: Armistice Capital, LLC (9.99%, Schedule 13G/A, filed 2026-08-14).
When did Armistice Capital, LLC buy into Imunon, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Armistice Capital, LLC on this page is the Schedule 13G, filed 2026-02-17, reporting 9.99%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Imunon, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 30, 2026 | Leadership change: Jeffrey Church departs, Chief Financial Officer, and 2 more | — | Leadership changes | Source |
| May 28, 2025 | Form D, private offering | $3.25M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Imunon, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.